BRPI0507732A - composição compreendendo l-serina, l-isoleucina, ácido fólico e micro elementos para tratamento da psorìase e uso desta - Google Patents

composição compreendendo l-serina, l-isoleucina, ácido fólico e micro elementos para tratamento da psorìase e uso desta

Info

Publication number
BRPI0507732A
BRPI0507732A BRPI0507732-0A BRPI0507732A BRPI0507732A BR PI0507732 A BRPI0507732 A BR PI0507732A BR PI0507732 A BRPI0507732 A BR PI0507732A BR PI0507732 A BRPI0507732 A BR PI0507732A
Authority
BR
Brazil
Prior art keywords
serine
isoleucine
folic acid
composition
microelements
Prior art date
Application number
BRPI0507732-0A
Other languages
English (en)
Inventor
Thomas Tallberg
Original Assignee
Helsingfors Institution F R Bi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsingfors Institution F R Bi filed Critical Helsingfors Institution F R Bi
Publication of BRPI0507732A publication Critical patent/BRPI0507732A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO OMPREENDENDO L-SERINA, L-ISOLEUCINA, àCIDO FóLICO E MICRO ELEENTOS PARA TRATAMENTO DA PSORìASE E USO DESTA". Meios médicos biológicos para tratamento da psoríase são descritos. A invenção relata ao uso de L-serina (Ser) e L-isoleucina IIe) para a manufatura de uma composição farmacêutica para tratamento e prevenção de psoríase. A invenção também relata a uma composição farmacêutica compreendendo os ditos aminoácidos como ingredientes ativos. Preferencialmente a invenção também compreende pelo menos um micro elemento essencial selecionado do grupo consistindo de cromo (Cr), estanho (Sn), selênio (Se), vanádio (V), tungstênio(w) e zinco (Zn) e ácido fólico.
BRPI0507732-0A 2004-02-06 2005-02-04 composição compreendendo l-serina, l-isoleucina, ácido fólico e micro elementos para tratamento da psorìase e uso desta BRPI0507732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20040180A FI121915B (fi) 2004-02-06 2004-02-06 Koostumus psoriasiksen hoitoon
PCT/FI2005/000075 WO2005074910A1 (en) 2004-02-06 2005-02-04 Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis

Publications (1)

Publication Number Publication Date
BRPI0507732A true BRPI0507732A (pt) 2007-07-10

Family

ID=31725662

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507732-0A BRPI0507732A (pt) 2004-02-06 2005-02-04 composição compreendendo l-serina, l-isoleucina, ácido fólico e micro elementos para tratamento da psorìase e uso desta

Country Status (17)

Country Link
US (1) US20070258892A1 (pt)
EP (1) EP1718290B1 (pt)
JP (1) JP4919812B2 (pt)
CN (1) CN1917868B (pt)
AT (1) ATE466576T1 (pt)
AU (1) AU2005210181B2 (pt)
BR (1) BRPI0507732A (pt)
CA (1) CA2555328C (pt)
DE (1) DE602005021062D1 (pt)
DK (1) DK1718290T3 (pt)
ES (1) ES2344510T3 (pt)
FI (1) FI121915B (pt)
NO (1) NO20063937L (pt)
PL (1) PL1718290T3 (pt)
PT (1) PT1718290E (pt)
RU (1) RU2372899C2 (pt)
WO (1) WO2005074910A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI122450B (fi) * 2007-12-28 2012-01-31 Neurofood Ab Oy Koostumus steriilin inflammaation hoitoon
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
CN101953846B (zh) * 2010-06-24 2011-12-28 攀枝花兴辰钒钛有限公司 一种药物组合物在制备治疗糖尿病的药物中的用途
EP2782566B1 (en) 2011-11-21 2021-01-06 The Institute for Ethnomedicine L-serine as for use in treating neurodegenerative disorders
EP3586849A1 (en) * 2018-06-29 2020-01-01 Aprofol AG Folate preparations
AU2020334128B2 (en) * 2019-08-21 2025-10-23 Brain Chemistry Labs Compositions comprising a metal and L-serine, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83775A (en) * 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
DE3712986A1 (de) * 1987-04-16 1988-10-27 Marbert Gmbh Medizinische zubereitungen auf der grundlage von biertreberextrakt, verfahren zu deren herstellung sowie verwendung von biertreberextrakt zur herstellung von kosmetischen zubereitungen und ein spezieller biertreberextrakt
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
CN1080131A (zh) * 1993-04-28 1994-01-05 王韵三 一种美容保健营养食品和制备方法
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
RU2071777C1 (ru) * 1995-01-13 1997-01-20 Тамара Васильевна Воробьева Способ получения средства, обладающего противоопухолевой активностью
US6083293A (en) * 1997-02-24 2000-07-04 Bath; Virginia L. Method for enhanced plant protein production and composition for use in the same
IT1299623B1 (it) * 1998-02-23 2000-03-24 Gen Topics Srl Composizione per uso cosmetico o farmaceutico a base di acido lipoico e acido piruvico
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
GB0019327D0 (en) * 2000-08-08 2000-09-27 Buchanan Baillie Hamilton Paul Slimming system
US20040086583A1 (en) * 2002-11-01 2004-05-06 Jensen Claude Jarakae Anti-angiogenesis effects of morinda citrifolia

Also Published As

Publication number Publication date
CN1917868B (zh) 2010-09-01
PT1718290E (pt) 2010-07-01
RU2006128209A (ru) 2008-03-20
WO2005074910A1 (en) 2005-08-18
FI121915B (fi) 2011-06-15
HK1097455A1 (en) 2007-06-29
FI20040180L (fi) 2005-08-07
JP2007520532A (ja) 2007-07-26
FI20040180A0 (fi) 2004-02-06
NO20063937L (no) 2006-09-04
DK1718290T3 (da) 2010-08-02
CA2555328A1 (en) 2005-08-18
ATE466576T1 (de) 2010-05-15
AU2005210181B2 (en) 2010-05-20
US20070258892A1 (en) 2007-11-08
ES2344510T3 (es) 2010-08-30
EP1718290B1 (en) 2010-05-05
JP4919812B2 (ja) 2012-04-18
AU2005210181A1 (en) 2005-08-18
EP1718290A1 (en) 2006-11-08
DE602005021062D1 (de) 2010-06-17
CN1917868A (zh) 2007-02-21
RU2372899C2 (ru) 2009-11-20
CA2555328C (en) 2013-03-26
PL1718290T3 (pl) 2010-10-29

Similar Documents

Publication Publication Date Title
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
ATE316786T1 (de) Behandlung von mukositis
BRPI0512397A (pt) composto,produto farmacêutico, métodos para suprimir a metástase de cáncer ou o crescimento do cáncer, para prevenir ou tratar uma doença ou condição, para controlar a função placentária, para melhorar a função gonadal, para induzir ou estimular a ovulação, para promover a secreção do hormÈnio gonadotrópico ou promover a secreção do hormÈnio sexual, para suprimir a secreção do hormÈnio gonadotrópico ou suprimir a secreção do hormÈnio sexual, para infra regular hormÈnio gonadrotópico ou hormÈnio sexual, e a proteìna ot7t175 humana, e para realçar a estabilidade no sangue, uso do composto, e, agente para suprimir a secreção do hormÈnio gonadotrópico ou um agente para suprimir a secreção do hormÈnio sexual
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
ATE482726T1 (de) Neuartiges mittel zur freisetzung von wirkstoffen in dressings mit mindestens einer fettigen substanz
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
BRPI0507732A (pt) composição compreendendo l-serina, l-isoleucina, ácido fólico e micro elementos para tratamento da psorìase e uso desta
BRPI0407814A (pt) derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose
BRPI0519070A2 (pt) composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
BRPI0514111A (pt) derivados de benzamidina, processo para a preparação destes e composição farmacêutica compreendendo os mesmos
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
ATE150019T1 (de) Beta-mercapto-propanamidderivate verwendbar zur behandlung kardiovaskularer krankheiten oder erkrankungen
US11376280B2 (en) Treating rotator cuff conditions
EP4491626A4 (en) PHENYLSULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER CONTAINING THEM AS ACTIVE INGREDIENT
DK2234611T3 (da) Sammensætning til behandling af steril inflammation
JP2009062312A (ja) ニキビ治療剤
BG66819B1 (bg) Средство за профилактика и лечение на заболявания на бъбреците и уринарния тракт
BRPI0417797A (pt) soro sangüìneo biologicamente ativo, métodos para produzi-lo e seus usos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: OY NEUROFOOD AB (FI)

Free format text: TRANSFERIDO DE: HELSINGFORS INSTITUTION FOR BIOIMMUNTERAPI AB.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.